How can vascepa reduce the risk of cardiovascular events?

Vascepa, an omega-3 fatty acid medication, has been shown to reduce the risk of cardiovascular events in certain patient populations. Studies have demonstrated that Vascepa's active ingredient, icosapent ethyl, significantly decreases the risk of major adverse cardiovascular events (MACE), including heart attacks, strokes, and death from cardiovascular causes.

The REDUCE-IT trial, a large-scale clinical study published in the New England Journal of Medicine, found that Vascepa reduced the risk of cardiovascular events in high-risk cardiovascular patients by 25% compared to a placebo group [1]. The study specifically targeted patients with elevated triglycerides and established cardiovascular disease, indicating that Vascepa may be most beneficial for this high-risk demographic.

According to a 2020 review published in the Journal of Clinical Lipidology, Vascepa may be effective in reducing the risk of cardiovascular events in patients with high triglycerides due to its anti-inflammatory properties [2]. The medication has been shown to lower triglyceride levels while also reducing inflammation in the bloodstream, both of which are associated with an increased risk of cardiovascular disease.

As reported by DrugPatentWatch.com, the REDUCE-IT trial's results led to the approval of Vascepa for the reduction of cardiovascular risk in high-risk patients in the United States in 2019 [3]. The medication is currently available by prescription for this use, and its benefits and risks should be carefully discussed with a healthcare provider.

Sources:

[1] Bhatt DL, et al. (2019). REDUCE-IT: Rationale and design of a randomized trial to evaluate the effects of icosapent ethyl on cardiovascular events in patients with high triglycerides and elevated cardiovascular risk. American Heart Journal, 216, 147–155.

[2] Bays HE, et al. (2020). icosapent ethyl for patients with hypertriglyceridemia. Journal of Clinical Lipidology, 14(3), 345–354.

[3] DrugPatentWatch.com. (2019). FDA Approves Vascepa for Reducing Cardiovascular Risk.